LeMaitre Vascular, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; filed August 8, 2023. LeMaitre develops and sells vascular medical devices and provides human-tissue cryopreservation services. Figures below are in U.S. dollars; financial statement amounts are in millions unless otherwise noted.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Net sales | $50.1 | $42.1 | $97.2 | $81.7 |
| Gross profit / margin | $32.1 / 64.0% | $27.8 / 66.0% | $63.0 / 64.8% | $53.8 / 65.8% |
| Operating income / margin | $9.5 / 18.9% | $5.8 / 13.7% | $17.3 / 17.8% | $13.7 / 16.8% |
| Net income | $8.1 | $3.5 | $14.1 | $9.6 |
| Diluted EPS | $0.36 | $0.16 | $0.63 | $0.43 |
- Growth: Sales rose 19% in both Q2 and the first half. Management attributed growth mainly to higher hospital procedure volumes, price increases, additional sales representatives, and the new porcine patch line. The porcine patches contributed $1.2 million in Q2 sales.
- Regions: Q2 sales increased 16% in the Americas, 26% in Europe, Middle East and Africa, and 21% in Asia Pacific. Biologics represented 49% of Q2 worldwide sales.
- Cash flow: First-half operating cash flow was $14.2 million, versus $14.0 million a year earlier. Investing used $12.6 million, including $7.2 million for marketable securities and $4.9 million for property, equipment and other assets. Financing used $1.3 million, including $6.2 million of dividends, partly offset by stock-option proceeds. Cash and cash equivalents increased $0.4 million from year-end to $19.5 million.
- Liquidity and debt: At June 30, cash and cash equivalents were $19.5 million and short-term marketable securities were $70.7 million, together about $90.2 million. Current assets were $174.5 million and current liabilities $25.9 million. The filing reports no borrowings; liabilities include $16.8 million of lease liabilities and acquisition-related obligations. Management said available cash, investments and interest income should meet anticipated cash needs for at least 12 months and known long-term requirements.
- Capital returns: The quarterly dividend rose to $0.14 per share from $0.125. A further $0.14 dividend was approved after quarter-end. A $25 million share-repurchase authorization runs through February 2024; no purchases had been made under the program by the filing date.
Material changes versus the prior comparable period
- Sales growth translated into higher gross profit, but gross margin fell 2.0 percentage points in Q2 and 1.0 point in the first half. Management cited higher labor costs, unfavorable product mix, manufacturing inefficiencies, and increased scrap and inventory-related charges.
- Sales and marketing expense rose 24% in Q2 and 31% year to date, primarily with higher sales-force headcount and commissions. R&D expense increased 35% and 34%, respectively, including higher regulatory consulting and testing costs. The sales force totaled 133 representatives, up 20% year over year.
- First-half net income increased to $14.1 million from $9.6 million; the prior-year comparison included $3.1 million of Q2 restructuring expense tied to the St. Etienne factory closure. LeMaitre recorded additional closure-related restructuring charges of $0.5 million in the first half of 2023.
- First-half foreign-exchange movements reduced reported sales by an estimated $1.1 million year over year. Short-term marketable securities carried an unrealized loss of $2.0 million due to rising interest rates.
Outlook, management commentary and risks
- The filing provides no clear numerical full-year revenue or earnings guidance. Management expects to fund operations and planned costs from existing resources, while noting that future capital needs depend on sales, dividends, acquisitions, expansion, regulatory work and potential repurchases.
- Commercial and operational initiatives include transitioning Thailand to direct hospital sales in Q3 2023, launching the PhasTIPP device more broadly in the second half of 2023, and completing CardioCel production transfers to Burlington. The MDR application for Burlington-made CardioCel products was submitted in June 2023; management anticipates an 18–24 month application process.
- Regulatory approvals are a significant risk. Nearly all products have been submitted for EU MDR review; delays or failure to obtain or maintain required CE or UKCA marks could affect sales, costs and product availability. The company noted that its Pruitt F3 CE mark under MDR did not cover polyurethane balloon models, which remain under the MDD mark.
- Other stated risks include product demand and acceptance, competition and pricing, acquisition integration, direct-sales transitions, foreign-currency movements, product recalls, and maintaining profitability. The company reported no legal matters it believed would materially adversely affect its financial position, results or cash flows as of August 8, 2023.
- Management reported effective disclosure controls as of June 30, 2023 and no material changes in internal control over financial reporting during the first half.
Important facts for investors to verify
- Whether sales growth and new-product contribution persist, and how much reflects volume, pricing, acquisitions or new distribution arrangements.
- Whether gross margin stabilizes as labor, product mix, manufacturing efficiency and scrap costs evolve.
- Progress and timing of MDR/CE approvals, including the CardioCel application and the Pruitt F3 models.
- Cash conversion and working-capital needs: first-half operating cash flow was affected by increases in receivables and inventory/deferred costs.
- Future use of liquidity for dividends, the authorized repurchase program, acquisitions and capital spending; confirm the value and risk profile of marketable securities.